Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences, a biotech firm specializing in immunomodulation therapies, has regained compliance with Nasdaq’s minimum bid price rule, canceling a scheduled hearing and ensuring its continued listing on the market. The company’s lead candidate, intranasal foralumab, is showing promising results in treating Non-Active Secondary Progressive Multiple Sclerosis, with an ongoing Phase 2a trial and an expanded access program. Tiziana’s innovative nasal delivery method for immunotherapy is patented, with several pending applications, highlighting its potential to enhance efficacy and safety over intravenous delivery.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
